🔬 Merck's Groundbreaking Announcement at CROI 2026

Merck has made waves in the HIV research community with late-breaking data from three pivotal Phase 3 clinical trials evaluating doravirine/islatravir (DOR/ISL), an investigational once-daily, two-drug regimen for treating adults living with human immunodeficiency virus type 1 (HIV-1). Presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver, Colorado, these findings were simultaneously published in the prestigious journal The Lancet HIV. This development marks a significant step forward in simplifying HIV management, potentially offering a non-integrase strand transfer inhibitor (non-INSTI) alternative to the dominant three-drug therapies currently in use.

The trials, known as MK-8591A-053, MK-8591A-052, and MK-8591A-051, demonstrated that DOR/ISL achieved non-inferior efficacy compared to standard regimens like bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF, marketed as Biktarvy) and baseline antiretroviral therapy (bART). With viral suppression rates hovering above 90% at week 48 across populations, including treatment-naïve patients and those switching from existing treatments, this regimen could address key challenges like treatment fatigue, comorbidities, and resistance concerns. For researchers and clinicians in infectious diseases, these results underscore the ongoing evolution of antiretroviral therapy (ART), where fewer pills and novel mechanisms are prioritized to improve long-term adherence.

Understanding Doravirine/Islatravir: The Science Behind the Two-Drug Combo

Doravirine (DOR), a non-nucleoside reverse transcriptase inhibitor (NNRTI), works by binding to the reverse transcriptase enzyme of HIV-1, preventing the virus from replicating its genetic material into host cells. Already approved in combination therapies like Delstrigo (DOR/lamivudine/tenofovir disoproxil fumarate), DOR has a well-established profile for potency against common NNRTI resistance mutations. Paired with islatravir (ISL), a novel nucleoside reverse transcriptase translocation inhibitor (NRTTI), the duo targets HIV at different stages of its lifecycle.

Islatravir stands out due to its unique mechanism: once inside cells, it gets phosphorylated into a form that blocks the translocation step during reverse transcription, halting viral DNA synthesis with high efficiency and a long intracellular half-life. This allows for the low once-daily dose of 0.25 mg in DOR/ISL, minimizing potential risks like lymphocyte declines seen in higher-dose earlier studies. The fixed-dose combination tablet simplifies dosing to one pill per day, a boon for patients managing lifelong therapy amid aging-related health issues.

In the context of HIV treatment history, regimens have progressed from complex multi-drug cocktails in the 1990s—often causing severe side effects—to today's streamlined single-tablet options. Yet, INSTI-based therapies like Biktarvy, while highly effective, carry risks of weight gain, neuropsychiatric effects, and integrase resistance. DOR/ISL's non-INSTI profile positions it as a valuable switch option, particularly for those with INSTI intolerance or virologic failure on prior regimens. Academic researchers in virology labs worldwide are closely watching, as this could spur studies on resistance patterns and long-term outcomes in diverse populations.

📊 In-Depth Look at the Three Phase 3 Trials

Each trial targeted specific patient groups to build a comprehensive efficacy and safety dataset for regulatory approval.

• MK-8591A-053 (NCT05705349): Focused on treatment-naïve adults new to ART. This double-blind, randomized study enrolled 536 participants across 116 sites in 20 countries, comparing DOR/ISL (100 mg/0.25 mg) to Biktarvy. At week 48, 91.8% on DOR/ISL achieved HIV-1 RNA below 50 copies/mL versus 90.6% on Biktarvy (difference 1.2%, 95% CI -3.7 to 6.2), meeting non-inferiority. Notably, in high viral load subgroups (>100,000 copies/mL), rates were 94.0% vs. 87.6%; for >500,000 copies/mL, 90.3% vs. 84.4%. CD4+ T-cell increases were comparable (218 vs. 226 cells/μL).
• MK-8591A-052: Evaluated switching virologically suppressed adults (HIV-1 RNA <50 copies/mL for ≥3 months) from Biktarvy to DOR/ISL. In 513 participants, virologic failure rates at week 48 were 1.5% vs. 0.6% (difference 0.9%, CI -1.9 to 2.9), with suppression at 98.5% vs. 99.4%. Extended to week 96, suppression held at 88.9% vs. 90.1%.
• MK-8591A-051 (NCT05631093): Assessed switches from various oral 2- or 3-drug bART in 551 suppressed adults. Week 48 failure: 1.4% vs. 4.9% (difference -3.6%, CI -7.8 to -0.8). At week 96, suppression reached 92.6-96.6%, with low failure rates.

These multinational trials included diverse demographics—median age around 32-51 years, significant representation of women, Black/African American, and Hispanic participants—ensuring broad applicability. For details, see the full publication in The Lancet HIV or ClinicalTrials.gov.

Safety Profile: Comparable and Reassuring

Safety was a cornerstone, with profiles mirroring comparators. Drug-related adverse events (AEs) were 14.1% (DOR/ISL) vs. 18.0% (Biktarvy) in naïve patients, with discontinuations at 1.1% vs. 2.2%. Common AEs included weight gain (3%), headache (2-3%), and dizziness (2%), but no new signals emerged. Crucially, at the 0.25 mg ISL dose, there were no discontinuations due to CD4+ declines or total lymphocyte counts (TLC), addressing prior concerns from higher doses.

Over 96 weeks in switch trials, AE discontinuations remained low (0.5-3.2%), and immune reconstitution was equivalent across arms. Serious AEs were infrequent and unrelated to treatment. This tolerability supports DOR/ISL's potential for long-term use, especially in aging patients with comorbidities like renal or bone issues linked to tenofovir.

Implications for HIV Treatment Landscape

Current HIV guidelines from bodies like the U.S. Department of Health and Human Services recommend INSTI-based three-drug regimens as first-line due to rapid viral suppression and high barrier to resistance. However, real-world challenges persist: up to 20-30% experience weight gain on INSTIs, and resistance affects 10-15% of treatment-experienced patients. DOR/ISL's success as the first non-INSTI two-drug regimen offers simplification without sacrificing efficacy, potentially reducing pill burden and drug interactions.

For virologically suppressed individuals—over 70% of the 39 million people living with HIV globally per UNAIDS 2025 data—this could mean easier switches, improving quality of life. In treatment-naïve cases, especially advanced disease (CD4 <200), robust performance signals versatility. Merck's Dr. Eliav Barr emphasized, "DOR/ISL may provide an important new option to meet evolving needs." Academics in clinical research jobs will find opportunities in post-approval studies monitoring resistance and real-world effectiveness.

Read Merck's full press release for executive insights.

Research and Academic Impact

This Merck milestone highlights the synergy between pharmaceutical innovation and academic research. Trials spanned universities and institutes like University Hospital Bonn, Case Western Reserve University, and Chulalongkorn University, involving experts in HIV pathogenesis and global health. Such collaborations drive discoveries in NRTTI mechanisms and resistance profiling, essential as HIV adapts.

For higher education professionals, the HIV field offers robust career paths in research jobs, from postdoctoral positions modeling viral dynamics to faculty roles leading cohort studies. With PDUFA date looming, expect surges in pharmacovigilance and implementation research. Platforms like Rate My Professor showcase educators shaping the next generation of virologists tackling global health inequities.

Photo by Logan Voss on Unsplash

Future Horizons: Regulatory Path and Beyond

The 48-week switch data supported Merck's New Drug Application (NDA) for suppressed adults, with FDA target action April 28, 2026. Positive readout could pave approvals worldwide, followed by label expansions. Islatravir's versatility shines in ongoing Phase 3 trials like ISLEND-1/2 with lenacapavir for once-weekly dosing—a game-changer for adherence.

As HIV transitions toward functional cures, two-drug regimens like DOR/ISL bridge to long-acting injectables. Researchers should monitor for real-world data on diverse clades and coinfections. Explore higher ed jobs in infectious diseases or craft a winning academic CV to join this vital field. Share your insights in the comments—what does this mean for HIV care?